Showing 1,681 - 1,700 results of 1,840 for search '"clinical researcher"', query time: 0.34s Refine Results
  1. 1681
  2. 1682
  3. 1683
  4. 1684
  5. 1685
  6. 1686
  7. 1687
  8. 1688
  9. 1689
  10. 1690

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  11. 1691
  12. 1692
  13. 1693
  14. 1694
  15. 1695
  16. 1696
  17. 1697
  18. 1698
  19. 1699

    A Machine Learning Model for Predicting Prognosis in HCC Patients With Diabetes After TACE by Wu L, Chen L, Zhang L, Liu Y, Ouyang D, Wu W, Lei Y, Han P, Zhao H, Zheng C

    Published 2025-01-01
    “…Linxia Wu,1– 3,* Lei Chen,1– 3,* Lijie Zhang,1,4,* Yiming Liu,1,5,* Die Ouyang,1 Wenlong Wu,5,6 Yu Lei,5,6 Ping Han,1 Huangxuan Zhao,1– 3 Chuansheng Zheng1– 3 1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430022, People’s Republic of China; 2Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430022, People’s Republic of China; 3Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, Hubei Province, 430022, People’s Republic of China; 4Department of Interventional Radiology, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, People’s Republic of China; 5Department of Interventional Radiology, Auto Valley Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430056, People’s Republic of China; 6Department of Interventional Radiology, Jinyinhu Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430048, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuansheng Zheng; Huangxuan Zhao, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430022, People’s Republic of China, Email hqzcsxh@sina.com; zhao_huangxuan@sina.comPurpose: Type II diabetes mellitus (T2DM) has been found to increase the mortality of patients with hepatocellular carcinoma (HCC). …”
    Get full text
    Article
  20. 1700